Quality and Outcomes

Gender differences in acute myocardial infarction—A nationwide German real-life analysis from 2014 to 2017

Leonie Kuehnemund MD1 | Jeanette Koepp PhD2 | Jannik Feld MSc2 | Achim Wiederhold MD1 | Julia Illner MD1 | Lena Makowski PhD1 | Joachim Gerß PhD2 | Holger Reinecke MD PhD1 | Eva Freisinger MD PhD1

1University Hospital Muenster, Cardiol., Dept. of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, Muenster, Germany
2Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany

Correspondence
Leonie Kuehnemund, Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure University Hospital Muenster, Albert-Schweitzer-Campus 1 D-48149 Muenster, Germany.
Email: leonie.kuehnemund@ukmuenster.de

Abstract

Background: Female sex was reported to be associated with an unfavorable outcome in acute myocardial infarction (AMI). In this nationwide analysis we assessed sex differences in acute outcomes of AMI and recent trends in patient healthcare.

Methods: We analyzed 875 735 German cases hospitalized with a main diagnosis of ST- (STEMI) and non ST-elevation myocardial infarction (NSTEMI) between January 01 2014 and December 31 2017 regarding morbidity, in-hospital mortality and treatments. A multivariable logistic regression model was designed to evaluate the use of interventions and their impact on in-hospital mortality.

Results: STEMI cases decreased from 72 894 in 2014 to 68 213 in 2017, with 70% assignable to men. Female sex was associated with older age (74 vs. 62 years), and higher prevalence of cardiovascular risk factors such as chronic kidney disease (19.2% vs. 12.5%), hypertension (69.0% vs. 65.0%) and left ventricular heart failure (36.0% vs. 32.1%). In NSTEMI, female sex was also associated with older age (78 vs. 71 years), and higher prevalence of cardiovascular risk factors such as chronic kidney disease (29.7% vs. 23.9%), hypertension (77.4% vs. 74.5%) and left ventricular heart failure (40.5% vs. 36.4%). Overall, 74.3% of female and 81.3% of male STEMI cases received percutaneous coronary intervention (PCI, p < 0.001). In NSTEMI, PCI was performed in 40.8% of female and 52.0% of male cases (p < 0.001). In-hospital mortality was notably increased in female patients with STEMI (15.0% vs. 9.6%; p < 0.001; OR 1.07; 95% CI 1.03–1.10) and NSTEMI (8.3% vs. 6.3%; p < 0.001; OR 0.91; 95% CI 0.89–0.93) compared to males.

Conclusions: Our nationwide real-world data document that in-patient STEMI cases continue to decrease in women and men. The observed higher in-hospital mortality in women was largely attributed to a more unfavorable risk and age distribution rather than to female-intrinsic factors. Women with AMI continue to be less likely to receive revascularization therapies.
1 | INTRODUCTION

Acute myocardial infarction (AMI) is still among the most common causes of death in men and women in industrialized nations. Differences related to patients’ sex have been reported for incidence, symptom presentation, pathophysiological characteristics as well as treatment strategies and outcome. However, awareness of the risk for heart disease in women is much lower than in men. Some studies have shown a negative association between female gender and outcome after AMI: specifically women experience more often delays to reperfusion, adverse events such as major bleeding events and complications associated with vascular access.

Many of the mentioned differences regarding therapy and complications have been attributed to the older average age of female patients at onset of AMI. So far, women are mostly underrepresented in guideline-changing cardiovascular disease research, often presenting less than a third of enrolled patients. In numerous studies, the interaction between gender, risk factors and incidence of myocardial infarction remains controversial. Some studies have suggested specific gender-intrinsic-causes even after adjustment for age and other risk factors, while others have failed to establish an association between gender and mortality.

As the primary objective of this routine-data-based analysis, sex differences of recent nationwide trends in in-patient healthcare and in-hospital outcome of AMI were evaluated. Furthermore, differences between both sexes of the association of comorbidities and in-hospital death were investigated to shed additional light on whether the increased mortality in women is due to a more unfavorable comorbidity of women or a potential gender-intrinsic factor.

2 | METHODS

The German remuneration system requires the coding of a main diagnosis for all in-hospital cases. This principal diagnosis must obligatorily reflect the underlying reason for hospitalization. In addition, an unlimited number of additional diagnoses can be coded in order to document coexisting morbidities as well as complications. The diagnoses must be coded in accordance to the German Modification of the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10-GM). Diagnostic, endovascular, and surgical procedures are coded in detail according to the German Procedure Classification (OPS). Diagnoses and procedures assigned to the respective ICD/OPS codes used in this analysis are listed in supplemental Table S1.

Due to federal law, all German hospitals are required to transfer the collected data on all in-hospitalizations to the national institute for hospital remuneration (Institut fuer das Entgeltsystem im Krankenhaus, InEK; Siegburg, Germany; http://www.g-drg.de) since 2002. Thanks to the Federal Statistical office, these large data records are available for scientific purposes after 2 years.

The data analyzed by the study at hand were given by administrative database base provided by the Federal Statistical Offices (Research Data Centre of the Federal Statistical Office and the Statistical Offices of the Länder [Statistisches Bundesamt [DESTATIS]; https://www.destatis.de]) contains all in-patient treated patients on a case base per year, except for treatments in psychiatric or psychosomatic units. There was only a remote access to anonymous data.

We identified all cases with a main diagnosis of ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) between Jan 1st 2014 and Dec 31st 2017 (using an ICD code I21* or I22* within 28 days after onset of symptoms). Further, data on concomitant diseases, risk constellations and selected cardiovascular procedures were acquired for sex-specific analysis. Covariables were determined by ICD codes as well, which were only available from inpatient diagnoses codes from the myocardial infarction hospitalization. Further details have been described previously.

2.1 | Statistics

The analysis covers all in-patient AMI cases in Germany and does not represent a subsample. All analyses were done for STEMI and NSTEMI cases separately. With regard to the primary question of this work, we want do address differences between female and male patients on in-hospital mortality, and differences between both sexes in the association of different factors for death in in-patient STEMI and NSTEMI cases. Furthermore, we want to address different in-hospital treatment strategies between female and male sex. Relative frequencies of death, in-hospital stroke, coronary intervention or surgery were tested via two-sided Chi-square test, in cases of large amount of data. Multivariable logistic regression analysis for in-hospital mortality was performed to evaluate the association of sex and in-hospital death adjusted by patient’s risk profile in a full model (including all patients) and for female and male sex separately. The models included age, diabetes mellitus (DM), chronic heart failure (CHF), chronic kidney disease (CKD), peripheral arterial disease (PAD), atrial fibrillation and/or flutter (Afib), hypertension, previous stroke, dyslipidemia, obesity, smoking, cancer and a disjoint categorical variable (no angiography, diagnostic angiography only without revascularization, PCI, CABG) to take account for different treatment strategies.

In order to address different patients risk profiles between female and male sex, we evaluated the interaction of gender with all other
TABLE 1 Baseline characteristics of patients hospitalized with AMI in 2014–2017

(A) STEMI

| Variable                              | Male; n (% within subgroup) | Female; n (% within subgroup) |
|---------------------------------------|-----------------------------|-------------------------------|
| Total (%)                             | 196 177 (64.7)              | 84 338 (35.3)                 |
| Age, median (IQR) (yrs)               | 62 (19)                     | 74 (20)                       |
| Anterior wall infarction, n (%)       | 93 903 (47.9)               | 40 693 (48.3)                 |
| Diabetes mellitus, n (%)              | 42 645 (21.7)               | 22 252 (26.4)                 |
| Chronic kidney disease, n (%)         | 24 548 (12.5)               | 16 157 (19.2)                 |
| Peripheral arterial disease 1–3, n (%)| 462 (2.4)                   | 1939 (2.3)                    |
| Critical limb threatening ischemia, n (%)| 1260 (0.6)                | 678 (0.8)                     |
| Atrial fibrillation, n (%)            | 25 552 (13.0)               | 14 864 (17.6)                 |
| Hypertension, n (%)                   | 128 266 (65)                | 58 434 (69)                   |
| NYHA I, n (%)                         | 6338 (3.2)                  | 2091 (2.5)                    |
| NYHA II, n (%)                        | 15 569 (7.9)                | 6149 (7.3)                    |
| NYHA III, n (%)                       | 18 480 (9.4)                | 9272 (11.0)                   |
| NYHA IV, n (%)                        | 22 852 (11.6)               | 12 630 (15.2)                 |
| Right ventricle chronic heart failure, n (%)| 8964 (4.6)                 | 6040 (7.2)                    |
| Chronic heart failure, n (%)          | 67 194 (34.3)               | 32 811 (38.9)                 |
| Cardiogenic shock, n (%)              | 23 102 (11.9)               | 11 272 (13.4)                 |
| Impella, n (%)                        | 1202 (0.6)                  | 398 (0.5)                     |
| ECMO, n (%)                           | 1753 (0.9)                  | 514 (0.6)                     |
| Dyslipidemia, n (%)                   | 96 639 (49.3)               | 37 004 (43.9)                 |
| Obesity, n (%)                        | 14 656 (7.5)                | 6766 (8.0)                    |
| Smoking, n (%)                        | 23 674 (12.1)               | 6249 (7.4)                    |
| Cancer, n (%)                         | 2648 (1.3)                  | 1254 (1.5)                    |

(B) NSTEMI

| Variable                              | Male; n (% within subgroup) | Female; n (% within subgroup) |
|---------------------------------------|-----------------------------|-------------------------------|
| Total (%)                             | 384 905 (69.9)              | 210 315 (30.1)                |
| Age, median (IQR) (yrs)               | 71 (19)                     | 78 (15)                       |
| Anterior wall infarction, n (%)       | 982 (0.3)                   | 479 (0.2)                     |
| Diabetes mellitus, n (%)              | 121 467 (31.6)              | 70 338 (33.4)                 |
| Chronic kidney disease, n (%)         | 92 120 (23.9)               | 62 485 (29.7)                 |
| Peripheral arterial disease 1–3, n (%)| 18 892 (4.9)                | 7505 (3.6)                    |
| Critical limb threatening ischemia, n (%)| 6150 (1.6)                 | 2957 (1.4)                    |
| Atrial fibrillation, n (%)            | 85 155 (22.1)               | 55 400 (26.3)                 |
| Hypertension, n (%)                   | 286 800 (74.5)              | 162 870 (77.4)                |
| Stroke, n (%)                         | 10 993 (2.9)                | 6973 (3.3)                    |
| NYHA I, n (%)                         | 8513 (2.2)                  | 4024 (1.9)                    |
| NYHA II, n (%)                        | 26 953 (7)                  | 14 130 (6.7)                  |
| NYHA III, n (%)                       | 45 608 (11.8)               | 27 279 (13)                   |
| NYHA IV, n (%)                        | 48 583 (12.6)               | 31 975 (15.2)                 |
| Right ventricle chronic heart failure, n (%)| 29 449 (7.7)              | 20 849 (9.9)                  |
| Chronic heart failure, n (%)          | 140 259 (36.4)              | 85 235 (40.5)                 |
| Cardiogenic shock, n (%)              | 14 803 (3.9)                | 7328 (3.5)                    |
| Impella, n (%)                        | 745 (0.2)                   | 299 (0.1)                     |

(Continues)
female and 2015 male STEMI patients aged 90 years and older, these received statistically notable less frequent PCI (42.5% female vs. 52.8% male; p < .001) and CABG (0.1% female vs. 0.4% male; p < 0.001) compared to younger age groups. In NSTEMI, PCI was performed in 40.8% of female and 52.0% of male cases (p < .001).

3.1 | In-hospital mortality

The observed in-hospital mortality was notably increased in female compared to male patients with STEMI with 12,672 (15%) versus 18,817 (9.6%) cases (p < .001). This was similar in NSTEMI with 17,502 (8.3%) versus 24,336 (6.3%) cases (p < .001; Figure 3). After adjustment for numerous co-factors, female sex remained an independent factor for increased in-hospital mortality in STEMI (OR 1.07; 95% CI 1.03–1.10; p < .001), while it was associated with lower mortality in NSTEMI (OR 0.91; 95% CI 0.89–0.93; p < .001). The outcome of AMI was also significantly altered by the patients’ co-morbidity as indicated by the encoded secondary diagnoses (Figure 4 and supplemental Table I).

Multivariable logistic regression analyses adjusted by patient’s risk profile for in-hospital death showed that chronic heart failure was associated with an decreased in-hospital mortality in STEMI and an increased in-hospital mortality in NSTEMI (STEMI: male OR 0.96; 95% CI 0.92–1.00; female OR 0.90; 95% CI 0.86–0.95; NSTEMI: male OR 1.51; 95% CI 1.46–1.56; female OR 1.49; 95% CI 1.44–1.55). A significant difference between women and men could not be shown (STEMI p\textsuperscript{int} = .106; NSTEMI p\textsuperscript{int} = .713).

Age was associated with an increased in-hospital mortality in STEMI and NSTEMI in both sexes, but a significant difference between men and women could only be seen in NSTEMI cases (p\textsuperscript{int} < .001).

The use of PCI in comparison to no angiography was associated with an decreased in-hospital mortality in case of NSTEMI (female: OR 0.31; 95% CI 0.29–0.32; male: OR 0.25; 95% CI 0.24–0.26) as well as in case of STEMI (female: OR 0.39; 95% CI 0.37–0.42; male: OR 0.35; 95% CI 0.33–0.37). A significant difference between men and women could be shown in case of STEMI (p\textsuperscript{int} < .001; Figure 4).

In addition, the use of CABG in comparison to no angiography decreased in-hospital mortality in both sexes (STEMI: women OR
0.49; 95%-CI 0.42–0.57 men OR 0.41; 95% CI 0.37–0.45; NSTEMI women OR 0.69, 95% CI 0.63–0.76; men OR 0.35; 95% CI 0.33–0.37). A significant difference between men and women could only be shown in case of NSTEMI (p < .001).

3.2 | Costs and length of hospital stay

The average (± standard deviation [STD]) cost per STEMI case was 7240 (±10 725) EUR in male and 6511 (±9181) EUR in female patients, and 6376 (±9398) EUR per male and 5367 (±7505) EUR per female NSTEMI case. The mean (STD) length of hospital stay for AMI was 8 (±8) days in male STEMI and 8 (±8) days in female STEMI and 8 (±8) days in male and 8 (±8) days in female NSTEMI cases.

4 | DISCUSSION

In this nationwide real-world setting including all AMI cases from Germany of the years 2014 to 2017, in-patient STEMI cases continue to decrease over the recent past in both, male and female patients. Furthermore, our data showed, that there were not only marked differences in baseline characteristics of in-patient STEMI and NSTEMI cases but also regarding the in-hospital treatment strategies between female and male patients. The manifestation of AMI in female patients occurred on average at an older age compared to men. Higher age and more frequent unfavorable comorbidities of women are discussed as the major cause for the higher in-hospital mortality in comparison to men. Moreover, the American Heart Association recommends to improve the under-representation of women in clinical trials due to the fact that data presented with sex- and gender-specific results are currently lacking in many studies.20

4.1 | In-hospital mortality and impact of comorbidities

In our study, the observed in-hospital mortality was notably increased in female patients with STEMI and NSTEMI compared to males. After adjustment to various influencing factors, female sex independently increased in-hospital mortality by almost 7% in the case of STEMI but was associated with decreased mortality in the case of NSTEMI. Previous published data from the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to
Recommended Therapies (SWEDEHEART) registry reported a similar trend, with a higher short-term mortality in female STEMI patients. This trend was driven by a high risk of cardiogenic shock in the pre-hospital-phase, which is not covered in our analysis. In their analyses, the authors concluded that the trend was age-dependent.21 A French study analyzed data from 74,389 patients hospitalized with acute myocardial infarction. Female patients had a higher rate of hospital mortality (14.8% versus 6.1%; p < .0001). As in our study, women in the French study were on average older (75 versus 63 years of age; p < .001).22 Nevertheless, there are also studies without any difference concerning in-hospital mortality due to gender. In a Polish nationwide study cohort of patients with AMI, female sex did not increase the in-hospital mortality (OR 0.97).23

4.2 | Impact of in-hospital treatment

Our results confirm prior studies,24,25 which showed that women presenting with acute coronary syndrome were less likely to undergo diagnostic catheterization as well as PCI than men although various studies have demonstrated a benefit from PCI for women and an association with a decreased in-hospital mortality.24,27,28

In our study, the use of PCI was associated with a decreased in-hospital mortality in case of STEMI as well as NSTEMI cases in both sexes. In contrast to this, studies such as FRISC-II and RITA-3-trial that concluded that women with NSTEMI do not benefit significantly from an early invasive treatment in comparison to a conservative treatment.29,30 In addition, a large study with 11,931 consecutive patients who underwent PCI for various indications during 2000–2009, showed that women undergoing PCI for STEMI had higher mortality than men. This could only partially be explained by a difference in baseline characteristics with more frequent unfavorable comorbidities.31

Female sex was also associated with decreased in-hospital mortality in case of CABG surgery. In the CADILLAC trial, the authors explain the higher mortality in women after interventional treatment by differences in lower body size as well as more unfavorable clinical risk factors.32 Reinecke et al. showed in their analyze of clinical and procedural data of 6681 patients who underwent PTCA and subsequent emergency CABG from 1989 to 1998 that women had an increased risk for failure of PTCA and a markedly higher operative mortality after emergency CABG. However, in multivariate analyses, female gender was not an independent predictor of postoperative death.33 In addition, some studies of coronary-artery bypass surgery

![Figure 3](image-url)

**Figure 3** In-hospital mortality dependent on sex. Observed (bars) data show in-hospital mortality of STEMI (panel A) and NSTEMI (panel B). The observed in-hospital mortality was notably increased in female compared to male patients with STEMI (15.0% vs. 9.6%; p < .001) and also in NSTEMI (8.4% vs. 6.3%; p < .001). NSTEM, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.
show increased perioperative mortality rate for women than men due to narrower coronary arteries, which may lead to more technical difficulties as well as less complete revascularization and lower success rates compared to men. However, long-term survival turned out to be similar.\textsuperscript{34,35,36}

One of many possible influencing factors explaining the differences may be a sex bias in the delivery of medical care. This could mean, that women undergo procedures later or men undergo procedures at a time when the disease is significantly less advanced and the outcome due to conservative care might not show a difference.

We also found an association between age and sex: differences due to the rate of invasive treatment (at least one out of diagnostic catheterization, PCI and/or CABG) widened with increasing age. A similar effect could be shown by Gan et al., who found that age was
associated with an increased in-hospital mortality in STEMI and NSTEMI in both sexes, but a significant difference between men and women could only be seen in NSTEMI cases.\textsuperscript{15}

4.3 Impact of costs and length of hospital stay

Both costs and length of stay are influenced by the patient's morbidity, diagnoses and procedures. Furthermore, due to the principles of the German DRG system, the length of the hospital stay has also impact on the costs incurred. Since women received less often interventions, this could be one reason why the total cost of stay was lower than that of men with an average of the same length of stay.

4.4 Strengths and limitations

One of the strengths of the presented data is the large-sized, unselected population of the entire nation which not only represent individual cases but allows us to analyze the real situation. The reliability and validity of the used ICD and OPS codes is high, because they directly impact the hospitals reimbursement. Furthermore, due to this high impact in reimbursement, all diagnostic and procedural codes are independently verified by the MDK (Medizinischer Dienst der Krankenversicherung/Medical Service of the Health Insurance) in more than 20\%–30\% of cases to assure that they are correct.

However, there are also some limitations of the study. The data were not patient- but case-based, which could result in some patients being counted twice in a year; however, this could only lead to underestimation of in-hospital mortality. In addition, the fact that the database is administrative and not clinical is also a limitation. Another limitation is the fact that the DESTATIS reflects only the hospital stay and any information after discharge is missing. In addition, these administrative data did not contain all clinically important information which may influence the outcome. The high percentage of patients who were coded as having NYHA IV heart failure may seem raise further questions about data reliability and could at least partly be due to the fact that people with heart failure NYHA IV may be transferred to other hospitals more often and are therefore counted twice in our analysis.

5 CONCLUSION

Our nationwide real-world data documented that the observed increased in-hospital mortality in female patients could largely attributed to the impact of the more unfavorable comorbidities and age, rather than due to female-intrinsic factors. With regard to standard coronary treatments (either diagnostic coronary angiography or PCI), female sex were associated with a decreased in-hospital mortality in STEMI and NSTEMI cases. Of note, female patients, and especially older women, received major diagnostic and therapeutic procedures less frequently than men.

Further studies will be needed to determine whether the differences in procedural rates reflect appropriate clinical practice or whether the outcome of women with acute coronary syndrome are negatively affected by these differences. Therefore, it is important that health care providers are made aware of potential sex differences in treatment, particularly in regard to the use of diagnostic catheterization in older patients.

ACKNOWLEDGMENT

Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

Lena Makowski reports other from Bayer Vital, outside the submitted work. Jannik Feld, Jeanette Koepppe, Julia Illner, Leonie Kuehnemund, Achim Wiederhold and Joachim Gerß have nothing to disclose. Holger Reinecke reports personal fees from Daichii, grants from BMS/Pfizer, personal fees from MedUpdate, personal fees from DiaPlan, personal fees from NeoVasc, grants and personal fees from Pluristem, grants from Bard, grants from Biotronik, personal fees from NovoNordisk, outside the submitted work. Eva Freisinger reports non-financial support from BAYER, non-financial support from Vascuors, outside the submitted work.

ETHICS STATEMENT

The data present here was assessed in the GenderVasc research project. This project was approved by the Ethics Committee of the Landesaerzettemaker Westfalen-Lippe and the Medical Faculty of the Westfaelische Wilhelms-University Muenster (No 2019-21-f-S).

DATA AVAILABILITY STATEMENT

The authors confirm that the data utilized in this study cannot be made available in the manuscript, the supplemental files, or in a public repository due to German data protection laws (‘Bundesdatenschutzgesetz’, BDSG). Generally, access to data of statutory health insurance funds for research purposes is possible only under the conditions defined in German Social Law (SGB V § 287). Requests for data access can be sent as a formal proposal specifying the recipient and purpose of the data transfer to the appropriate data protection agency. Access to the data used in this study can only be provided to external parties under the condition of the cooperation contract of this research project and after written approval by the sickness fund.

ORCID

Leonie Kuehnemund https://orcid.org/0000-0002-3430-5895
Eva Freisinger https://orcid.org/0000-0002-4409-3179

REFERENCES

1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organization and United Nations. Int J Cardiol. 2013;168:934-945.

2. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National registry of myocardial infarction 2 participants. N Engl J Med. 1999;341:217-225. https://doi.org/10.1056/NEJM199907223410401.

3. Lichtman JH, Wang Y, Jones SB, et al. Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: evidence from the NCDR\textsuperscript{(TM)}. Am Heart J. 2014;167:376-383. https://doi.org/10.1016/j.ahj.2013.11.001.

4. Mosca L, Hammond G, Mohr-Chernberger H, et al. American Heart Association Cardiovascular D, Stroke in W, Special Populations Committee of the Council on Clinical Cardiology CoE, Prevention CoCNCoHB. Fifteen-year trends in awareness of heart disease in
women: results of a 2012 American heart association national survey. Circulation. 2013;127:1254-1263.

5. Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation. 2001;104:3034-3038.

6. Radovanovic D, Erne P, Urban P, et al. On behalf of the AMIS plus investigators. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20 290 patients from the AMIS plus registry. Heart. 2007;93:1369-1375.

7. Hess CN, McCoy LA, Duggirala HJ, et al. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from translate-acs. J Am Heart Assoc. 2014;3:e000523. https://doi.org/10.1161/JAHA.113.000523.

8. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global use of strategies to open occluded coronary arteries in acute coronary syndromes IIb investigators. N Engl J Med. 1999;341:226-232. https://doi.org/10.1056/NEJM1999072234104042.

9. Peterson ED, Lansky AJ, Anstrom KJ, Lanzilotta MJ. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol. 2001;88:359-364. https://doi.org/10.1016/s0002-9149(01)01679-4.

10. Sama AA, Braunwald E, Cannon CP, et al. Outcomes of women compared with men after non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2019;74(24):3013-3022.

11. Peters SA, Colantonio LD, Dai Y, et al. Trends in recurrent Coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation. 2021;143:650-660.

12. Mellon C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3(2):135-142.

13. Loyeau A, Benamer H, Bataille S, et al. Evolution of ST-elevation acute myocardial infarction prevalence by gender assessed age pyramid analysis—the Piramyd study. J Clin Med. 2018;7(12):509.

14. Blöndal M, Ainla T, Marandi T, Baburin A, Eha J. Sex differ- ences between 2008 and 2017. Circulation. 2014;35:262-268.

15. Milcent C, Golding LR, MacMillan JP, et al. Coronary artery surgery in women and men. J Thorac Cardiovasc Surg. 2013;145:940-953.

16. Reinecke H, Roeder N, Schmid C, et al. Outcome of women is impaired in patients undergoing emergency coronary artery bypass grafting for failed PTCA. Z Kardiol. 2001;90(10):729-736.

17. Freisenger E, Fuerstenberg T, Malýr NM, et al. Gender nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life. Eur Heart J. 2014;35:979-988.

18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1):289-300.

19. Mehta L, Beckie T, DeVon H, et al. Acute myocardial infarction in women. A scientific statement from the American Heart Association. Circulation. 2016;133:916-947.

20. Redfors B, Angerås O, Råmunddal T, et al. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish web system for enhancement of evidence-based Care in Heart Disease Evaluated According to recommended therapies (SWEDHEART). J Am Heart Assoc. 2015;4(7): e001995. https://doi.org/10.1161/JAHA.115.001995.

21. Milcent C, Domont B, Duran-Zaleski I, et al. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 Nationwide French hospitals database. Circulation. 2007;115(7):833-839.

22. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–2012—nationwide AMI-PL database. Kardiol pol. 2015;73:142-158.

23. Heer T, Gitt AK, Juenger C, et al. ACOS investigators. Gender differences in acute non-ST-segment elevation myocardial infarction. Am J Cardiol. 2006;98(2):160–166.

24. Heer T, Schiele R, Schneider S, et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol. 2002;89:511-517.

25. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? BMJ. 1994; 309:563-566.

26. Mehlli J, Ndrepepa G, Kastrati A, et al. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. J Am Coll Cardiol. 2005;45:828.

27. Mueller C, Neumann FJ, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. J Am Coll Cardiol. 2002;40:245-250.

28. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J. 2004;25:1641-1650.

29. de Boer SP, Roos-Hesselink JW, van Leeuwen MA, et al. Excess mortality in women compared to men after PCI in STEMI: an analysis of 11,931 patients during 2000-2009. Int J Cardiol. 2014;176(2):456-463. https://doi.org/10.1016/j.ijcard.2014.07.091.

30. Lanksy AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American. Circulation. 2005;111(7):940-953.

31. Reinecke H, Roeder N, Schmid C, et al. Outcome of women is impaired in patients undergoing emergency coronary artery bypass grafting for failed PTCA. Z Kardiol. 2001;90(10):729-736.

32. Douglas JS Jr, King SB III, Jones EL, et al. Reduced efficacy of coronary bypass surgery in women. Circulation. 1981;64(Suppl II):11-16.

33. Fisher LD, Kennedy JW, Davis KB, et al. Association of sex, physical size, and operative mortality after coronary artery bypass in the coronary artery surgery study (CASS). J Thorac Cardiovasc Surg. 1982;84:334-341.

34. Loop FD, Golding LR, MacMillan JP, et al. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol. 1983;1:383-390.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.